11.11.19 Treatment of SLE Patients with the Immunoproteasome Inhibitor KZR-616: Results From the First 3 Cohorts of an Open-label Phase 1b Dose Escalation Trial. American College of Rheumatology Annual Meeting 2019 (ACR/ARP 2019).
